Novo's shares have dropped more than 60% over the past couple of years as it lost market share in GLP-1 products such as Wegovy, Ozempic, and Rybelsus to Eli Lilly. Its 2030 goals include more than five products each generating several billion dollars in annual sales, revenue growth comparable to industry peers, serving 10 times as many obese patients with oral GLP-1 products, and reaching more than 60 million patients, up from over 45.6 million last year. Candidates such as CagriSema, awaiting approval after beating Wegovy in a head-to-head Phase 3 obesity study, and zenagamtide, in Phase 3 trials, are seen as having blockbuster potential. The author judges Novo fairly well-positioned to reach these goals, helped by licensed candidates such as UBT251 and HRS-1596, while the stock trades at about 12x forward earnings versus an average of 19.2x for healthcare stocks, though clinical setbacks remain a risk.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on Yahoo Finance ↗
Keywords
Novo Nordiskpharmaceuticalshealthcarevaluation
Open a keyword to see other news on the same topic.
Related news
- Novo Nordisk and Eli Lilly Just Got Some Fantastic News
A mouse study funded by the NIH found that semaglutide, made by Novo Nordisk and sold as Ozempic and Wegovy, extended the lifespan of older, healthy mice by tempering aging effects, with treated mice showing better muscle and cognitive function. The author assumes that tirzepatide, Eli Lilly's main GLP-1 drug, could show similar effects, though results in humans remain a long way off. Gallup data cited in the article show that US adult use of GLP-1 weight-loss injectables has nearly quadrupled since 2024, reaching 11% this year from 3% two years ago. J.P. Morgan expects about 25 million Americans to be on GLP-1 treatment by 2030, and Morgan Stanley forecasts the market will more than double from 2025 to 2035, to $190 billion.
- Where Will Novo Stock Be in 10 Years?
Novo, a Denmark-based pharmaceutical company, reached an all-time high in 2024 but has since faced clinical and commercial setbacks and lost substantial market value over the past two years. Its diabetes products, including Ozempic and Rybelsus, and its obesity drug Wegovy remain core, but U.S. patents on the active ingredient in these drugs expire in 2032, potentially opening the door to cheaper generics. Near-term catalysts include CagriSema, which could be approved by year-end and combines semaglutide with cagrilintide, though it fell short of the 25% mean weight loss Novo had hoped for. The pipeline also includes amycretin, UBT251, and several oral weight loss candidates. The author sees the pipeline as deep but warns of rising competition from dozens of weight-loss drugs, slower market growth, and possible U.S. drug price negotiations.
- Novo's CagriSema Delivered 25% Weight Loss in Women. Could It Help Turn Around the Beaten-Down Stock?
Novo Nordisk presented a post hoc analysis of a Phase 3 CagriSema trial at The Menopause Society meeting: after 68 weeks, 2,309 women lost almost 25% of body weight on average, versus 3% on placebo. Among 1,902 women with menopause-related overweight or obesity, mean loss ranged from 23% to nearly 27%, while placebo averaged 2%. These results beat or match Wegovy (just under 15%) and Zepbound (nearly 21%), though in the head-to-head Redefine 4 trial, tirzepatide, Zepbound's molecule, showed similar or slightly higher efficacy, nearly 26% at the maximum dose. The author argues CagriSema is unlikely to win back market share from Eli Lilly, so investors should watch Novo's other pipeline programs, and notes the figures assume patients use the drug as directed.
- Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis
Novo said its next-generation obesity drug CagriSema led to an average 25% weight loss among women at 68 weeks in a new analysis following a late-stage trial, versus 3% with placebo. The result assumes all patients stayed on treatment without interruption, and Novo says further work is needed to confirm two post-study analyses. A separate analysis of about 1,900 women found weight loss of 26.7% in premenopausal, 24.8% in perimenopausal and 23.1% in postmenopausal women. The drug is expected to launch early next year, though investors have been lukewarm after earlier trial results fell short of expectations, and analysts forecast $11.84 billion in 2028 obesity sales per FactSet consensus.
- Novo Trades at Less Than 12 Times Earnings. Is This the Buying Opportunity of the Decade?
Novo's shares have fallen more than 60% after losing GLP-1 market share to Eli Lilly, and the stock trades at 11.8x forward earnings versus an 18.6x average for healthcare stocks. The article cites clinical setbacks, including CagriSema missing a 25% mean weight-loss target and losing a head-to-head trial to Zepbound, plus a failed Phase 3 study of ziltivekimab. Second-quarter net sales rose 2% to 78.5 billion Danish kroner, and adjusted earnings per share rose 5% to 6.18 DKK. Oral Wegovy has helped widen the market, and the pipeline includes zenagamtide, which showed up to 24.3% mean weight loss over 36 weeks in an early study. The author concludes Novo is not a once-in-a-decade buy, though it could deliver solid returns over the medium term.
- 7 healthcare stocks that stand out as investors pay up for the sector
Related markets
Latest news
- What Eldorado Gold (EGO) Said on Its Q3 Earnings Call
Eldorado Gold said commercial production at its Skouries project is now expected in late 2026, with total project capital rising to about $1.425 billion, though the company says the project remains fully funded. Third-quarter revenue rose 18% year over year to $512 million, supported by an average realized gold price of $4,326 per ounce versus $3,527 a year earlier, and adjusted earnings reached $0.49 per share compared with $0.41. Consolidated free cash flow was negative $191 million as the company continued investing in Skouries and McIlvenna Bay. Eldorado cut 2026 gold production guidance for its established mines to 410,000–430,000 ounces, excluding the two new projects, which are expected to reach nameplate capacity around mid-2027. The company has offtake contracts covering most expected Skouries output over the next two and a half years.
- Could Apple's First Touchscreen MacBook Pro, First Foldable iPhone Duo Phone, and HomeView Pole Vault Apple Beyond Nvidia to Become the First Company in the $10 Trillion Club?
Nvidia became the first company to reach a $5 trillion market capitalization last year on the back of the AI boom, but its shares have recently been pressured by concerns over AI financing, while Apple has hit record highs and at one point in a recent session passed Nvidia as the most valuable company. Apple's rally is driven by consumer devices, including the foldable iPhone Duo, the HomeView smart home display and a touchscreen MacBook Pro. Apple's fiscal third-quarter revenue rose 16%, and between Oct. 6 and Oct. 23 its market value rose about 4% while Nvidia's fell nearly 12%. Reaching $10 trillion would require Apple's value to climb nearly 100% from about $5.1 trillion today, and the stock trades at about 37 times forward earnings, with analysts expecting roughly 8% earnings growth next year. The author views $10 trillion as a long-term possibility rather than a near-term outcome, and says Nvidia may be just as likely to reach it first.
- Oracle Just Capped How Much New Money It Will Raise. I'd Consider Buying a Small Stake in the Stock.
At its investor day, Oracle repeated targets of at least $225 billion in fiscal 2030 revenue and $21 per share in non-GAAP earnings. Oracle will cap new stock and debt at $20 billion over fiscal 2027–2030, split $10 billion each, on top of $20 billion of stock already sold, versus $48 billion raised in fiscal 2026 when free cash flow was negative $23.7 billion. Management expects free cash flow to turn positive in the second half of fiscal 2028 and reach $30 billion or more in fiscal 2029. The author notes shares near $145 are down about 56% from their record close, and that at about 18 times the $8.10 adjusted earnings expected this fiscal year, the price looks reasonable. The author would consider a small stake and add more once capital spending starts to fall.
- 'Whale' Investors Rush to Pull Crypto Off Exchanges After Binance Hack
Institutional investors are rapidly withdrawing assets from centralized exchanges after the Binance hack to reduce security risks, according to CoinDesk, though the size of these outflows and their destinations have not been determined. Binance estimates total stolen assets at about 6.3 billion USD, of which around 3 billion USD has been frozen, including 2.3 billion USD in the stablecoins USDT and USDC. The main cause may involve a compromised laptop belonging to an engineer; Binance has temporarily suspended withdrawals, and co-CEO Yi He said the platform will cover all losses from the attack. Bitcoin dipped to a low of about 76,460 USD, and total liquidations reached 1.53 billion USD over 24 hours, nearly 84% of them long positions.
- The Smartest AI Stock to Buy on Anthropic's IPO Filing Isn't Anthropic
Anthropic has filed an S-1 with the SEC, signaling a future IPO, and lists Nvidia among its major industry partners. The author notes Anthropic uses multiple chips, and Nvidia's GPUs are heavily used in cloud environments where customers run Claude-based products. Nvidia expects global AI data center capital expenditures to reach $3 trillion to $4 trillion annually by 2030 and has guided for 70% revenue growth in 2027. Yet the stock trades at about 23 times this year's earnings estimates, 13.6 times next year's, and 27 times trailing earnings, which the author says does not reflect growth beyond 2026. The author argues Nvidia remains a strong AI investment, and other companies' 2027 spending plans could confirm that view.
- Trump Reveals Why the US Sent a Letter to Iran's Leaders
President Donald Trump denied directing Vice President JD Vance to send a letter to Iran to explore resuming peace talks, saying Vance proposed it to offer medical supplies. The Wall Street Journal, citing a source, reported the letter was sent on Trump's instructions and aimed to persuade Trump against a sudden, large-scale strike on Iran. Iran's Tasnim news agency said Tehran received the letter but has not responded, and repeated conditions including lifting the US naval blockade of Iranian ports and ending sanctions on its oil exports. A senior Iranian official said proposals from Qatar were unacceptable, while US military options remain under consideration after Admiral Brad Cooper briefed Trump at the White House.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.